^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET fusion

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE) (NCT04892953)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/07/2021
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    EGFR • ALK • MET • RET • ROS1
    |
    RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) (NCT04819100)
    Phase 3
    Eli Lilly and Company
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/20/2021
    Primary completion :
    05/01/2027
    Completion :
    08/01/2032
    RET
    |
    RET fusion
    |
    Retevmo (selpercatinib)
    Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities ((MARGARET)) (NCT04683250)
    Phase 1/2
    Taiho Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/16/2020
    Primary completion :
    03/01/2030
    Completion :
    03/01/2031
    RET
    |
    RET fusion
    |
    vepafestinib (TAS0953/HM06)
    A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET Lung) (NCT04222972)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/24/2020
    Primary completion :
    01/27/2025
    Completion :
    01/27/2025
    RET
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) (NCT04194944)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    02/17/2020
    Primary completion :
    05/01/2023
    Completion :
    06/01/2026
    RET
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Retevmo (selpercatinib) • pemetrexed
    Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (Lung-MAP Sub-Study) (NCT05364645)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/25/2022
    Primary completion :
    06/27/2023
    Completion :
    05/01/2029
    EGFR • KRAS • BRAF • ALK • MET • RET • ROS1
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
    |
    carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (NCT05170204)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    11/01/2022
    Primary completion :
    06/17/2029
    Completion :
    04/14/2035
    PD-L1 • RET • ROS1
    |
    RET fusion • ALK fusion • ROS1 fusion
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)
    Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (LUNG-MAP Sub-Study) (NCT04268550)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/08/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    EGFR • KRAS • BRAF • ALK • MET • RET • ROS1
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
    |
    Retevmo (selpercatinib)
    The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (NCT06109558)
    Phase 1/2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/31/2023
    Primary completion :
    12/30/2026
    Completion :
    07/30/2027
    EGFR • MET • RET
    |
    MET amplification • RET fusion • EGFR T790M negative
    |
    Tagrisso (osimertinib)
    The Efficacy and Safety of IBI363 in Solid Tumors (Promise) (NCT06081907)
    Phase 1/2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/25/2023
    Primary completion :
    12/01/2026
    Completion :
    09/01/2028
    EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK
    |
    BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation
    |
    erlotinib • Lenvima (lenvatinib)
    Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations (NCT05845671)
    Phase 1/2
    University of Colorado, Denver
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    07/11/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2028
    RET • ROS1
    |
    RET fusion • ALK fusion • ROS1 fusion
    |
    Rybrevant (amivantamab-vmjw)
    SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer (NCT05570825)
    Phase 2
    University of Washington
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/06/2023
    Primary completion :
    07/01/2027
    Completion :
    07/01/2028
    PD-L1 • ALK • RET • ROS1
    |
    PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)
    Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations (NCT05701787)
    Phase N/A
    Shanghai Chest Hospital
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    01/01/2019
    Primary completion :
    12/31/2028
    Completion :
    12/31/2029
    EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion
    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) (NCT03037385)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/11/2024
    Initiation :
    03/17/2017
    Primary completion :
    03/21/2024
    Completion :
    03/21/2024
    RET
    |
    RET fusion • RET mutation • RET rearrangement
    |
    Gavreto (pralsetinib)
    A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (NCT05241834)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    03/23/2022
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    RET
    |
    RET fusion • RET mutation
    |
    LOXO-260
    A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (NCT03157128)
    Phase 1/2
    Loxo Oncology, Inc.
    Recruiting
    Last update posted :
    03/04/2024
    Initiation :
    05/02/2017
    Primary completion :
    02/28/2025
    Completion :
    02/28/2026
    RET
    |
    RET fusion
    |
    Retevmo (selpercatinib)
    Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor (NCT05225259)
    Phase N/A
    Eli Lilly and Company
    No Longer Available
    Last update posted :
    02/28/2024
    RET
    |
    RET fusion • RET mutation
    |
    LOXO-260
    A Study of TY-1091 in Patients With Advanced Solid Tumors (NCT05675605)
    Phase 1/2
    TYK Medicines, Inc
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    04/24/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    RET
    |
    RET fusion
    |
    TY-1091
    Targeted Therapy to Increase RAI Uptake in Metastatic DTC (NCT05024929)
    Phase N/A
    Children's Hospital of Philadelphia
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    07/16/2021
    Primary completion :
    02/01/2031
    Completion :
    02/01/2033
    BRAF • ALK • RET • NTRK
    |
    BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion
    Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (NCT04322591)
    Phase N/A
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    03/24/2020
    Primary completion :
    12/24/2024
    Completion :
    03/24/2025
    RET
    |
    RET fusion • RET positive
    Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) (NCT02314481)
    Phase 2
    University College, London
    Active, not recruiting
    Last update posted :
    12/04/2023
    Initiation :
    05/12/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    HER-2 • BRAF • ALK • RET
    |
    HER-2 amplification • BRAF V600 • RET fusion • ALK fusion
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine)
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (NCT03780517)
    Phase 1
    Boston Pharmaceuticals
    Completed
    Last update posted :
    10/30/2023
    Initiation :
    12/12/2018
    Primary completion :
    09/26/2023
    Completion :
    09/26/2023
    RET
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) (NCT05788926)
    Phase 1
    Transgene
    Recruiting
    Last update posted :
    10/20/2023
    Initiation :
    04/05/2023
    Primary completion :
    10/30/2024
    Completion :
    03/31/2025
    EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1
    |
    BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12
    |
    TG6050
    Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer (NCT06067776)
    Phase 1
    Jonathan Riess
    Not yet recruiting
    Last update posted :
    10/05/2023
    Initiation :
    01/01/2024
    Primary completion :
    01/01/2025
    Completion :
    11/01/2026
    HER-2 • BRAF • ALK • MET • RET
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)
    Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC (NCT06031558)
    Phase 3
    Shouyao Holdings (Beijing) Co. LTD
    Recruiting
    Last update posted :
    09/21/2023
    Initiation :
    06/20/2023
    Primary completion :
    09/20/2024
    Completion :
    06/20/2026
    RET
    |
    RET fusion • RET positive
    |
    SY-5007
    OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer (NCT05935774)
    Phase 2
    University of Washington
    Withdrawn
    Last update posted :
    08/25/2023
    Initiation :
    12/01/2023
    Primary completion :
    07/31/2028
    Completion :
    07/31/2028
    HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK
    |
    BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion
    |
    Tecentriq (atezolizumab) • trabedersen (OT-101)
    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity (NCT01639508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/26/2023
    Initiation :
    07/01/2012
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    RET • ROS1 • KIF5B • AXL • NTRK
    |
    RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion
    |
    Cabometyx (cabozantinib tablet)
    A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions (NCT05653869)
    Phase 1
    Applied Pharmaceutical Science, Inc.
    Recruiting
    Last update posted :
    06/15/2023
    Initiation :
    02/06/2023
    Primary completion :
    04/01/2024
    Completion :
    04/01/2025
    RET
    |
    RET fusion • RET mutation
    |
    APS03118
    Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC (NCT05668962)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    04/13/2023
    Initiation :
    03/01/2023
    Primary completion :
    03/01/2024
    Completion :
    01/01/2025
    RET • TG
    |
    RET fusion
    |
    Retevmo (selpercatinib)
    Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (NCT05278364)
    Phase 1/2
    Shouyao Holdings (Beijing) Co. LTD
    Recruiting
    Last update posted :
    04/12/2023
    Initiation :
    04/23/2021
    Primary completion :
    01/01/2025
    Completion :
    02/10/2025
    PD-L1 • RET
    |
    RET fusion • RET mutation • RET positive
    |
    SY-5007
    Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC (NCT05800340)
    Phase 2
    Guangdong Provincial People's Hospital
    Recruiting
    Last update posted :
    04/05/2023
    Initiation :
    04/04/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    HER-2 • PD-L1 • BRAF • MET • RET
    |
    BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • pemetrexed
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (NCT05117658)
    Phase 2
    CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Recruiting
    Last update posted :
    08/04/2022
    Initiation :
    02/18/2022
    Primary completion :
    10/01/2023
    Completion :
    10/01/2023
    RET
    |
    RET fusion
    |
    HA121-28
    Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) (NCT05099068)
    Phase N/A
    Centre Leon Berard
    Recruiting
    Last update posted :
    07/04/2022
    Initiation :
    11/16/2021
    Primary completion :
    09/15/2025
    Completion :
    09/15/2025
    RET
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • RET fusion • RET mutation
    Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors (NCT02691793)
    Phase 4
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    11/20/2017
    Primary completion :
    08/30/2019
    Completion :
    11/19/2019
    RET • FGFR2
    |
    RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive
    |
    sunitinib
    Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors (NCT02450123)
    Phase N/A
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    03/23/2016
    Primary completion :
    08/30/2019
    Completion :
    11/05/2019
    RET • FGFR
    |
    RET fusion • FGFR amplification • RET positive
    |
    sunitinib
    Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC (NCT04204928)
    Phase N/A
    Blueprint Medicines Corporation
    Approved for marketing
    Last update posted :
    08/13/2021
    EGFR • BRAF • ALK • RET • ROS1 • NTRK
    |
    EGFR mutation • BRAF mutation • RET fusion • RET mutation
    |
    Gavreto (pralsetinib)
    External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446)
    Phase N/A
    Blueprint Medicines Corporation
    Enrolling by invitation
    Last update posted :
    08/10/2021
    Initiation :
    12/01/2020
    Primary completion :
    10/31/2021
    Completion :
    10/31/2021
    RET
    |
    RET fusion • RET positive
    |
    cisplatin • Gavreto (pralsetinib)
    Vandetanib in Advanced NSCLC With RET Rearrangement (NCT01823068)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    12/07/2020
    Initiation :
    11/03/2014
    Primary completion :
    12/29/2014
    Completion :
    03/16/2018
    RET
    |
    RET fusion
    |
    Caprelsa (vandetanib)
    Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc (CELTICS) (NCT04624373)
    Phase N/A
    University Hospital, Toulouse
    Not yet recruiting
    Last update posted :
    11/10/2020
    Initiation :
    12/31/2022
    Primary completion :
    12/31/2022
    Completion :
    12/31/2022
    EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK
    |
    KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • RET fusion • ALK rearrangement • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation
    AUY922 in Patient With Stage IV NSCLC (NCT01922583)
    Phase 2
    National Taiwan University Hospital
    Completed
    Last update posted :
    07/18/2018
    Initiation :
    01/01/2014
    Primary completion :
    02/01/2017
    Completion :
    02/01/2017
    EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2
    |
    BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation
    |
    luminespib (AUY922)
    Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer (NCT02540824)
    Phase 2
    Tongji University
    Unknown status
    Last update posted :
    09/04/2015
    Initiation :
    01/01/2015
    Primary completion :
    12/01/2016
    Completion :
    12/01/2017
    RET
    |
    RET fusion • RET positive
    |
    AiTan (rivoceranib)